BRAIN and NERVE－神経研究の進歩71巻5号

2019年05月発行

特集 NPSLE

NPSLEの臨床—脳神経内科の立場から

著者： 杉山淳比古¹ 桑原聡¹

所属機関： ¹千葉大学大学院医学研究院脳神経内科学

ページ範囲：P.459 - P.471

文献概要

全身性エリテマトーデス（SLE）に伴って見られる神経精神症状（NPSLE）の表現型は多様である。SLEの初発症状としてNPSLEが出現し得るため，SLEと未診断の神経精神症状を呈する患者からSLEを見抜く必要がある。また，SLE患者が経過中に神経精神症状を呈した場合，SLEに起因するprimary NPSLEなのか，治療薬の副作用や他疾患によるものかを正確に判断することも治療方針決定に重要である。

参考文献

1)ACR ad hoc Committee on Neuropsychiatric Lupus Nomenclature: The American college of rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 42: 599-608, 1999

2)Ainiala H, Hietaharju A, Loukkola J, Peltola J, Korpela M, et al: Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a population-based evaluation. Arthritis Rheum 45: 419-423, 2001

3)Covoni M, Bortoluzzi A, Padovan M, Silvagni E, Borrelli M, et al: The diagnosis and clinical management of the neuropsychiatric manifestations of lupus. J Autoimmun 74: 41-72, 2016

4)Zirkzee EJ, Huizinga TW, Bollen EL, van Buchem MA, Middelkoop HA, et al: Mortality in neuropsychiatric systemic lupus erythematosus (NPSLE). Lupus 23: 31-38, 2014

5)Hanly JG, Urowitz MB, Su L, Sanchez-Guerrero J, Bae SC, et al: Short-term outcome of neuropsychiatric events in systemic lupus erythematosus upon enrollment into an International Inception Cohort Study. Arthritis Rheum 59: 721-729, 2008

6)Hanly JG, Urowitz MB, Su L, Bae SC, Gordon C, et al: Prospective analysis of neuropsychiatric events in an International Disease Inception Cohort of SLE patients. Ann Rheum Dis 69: 529-535, 2010

7)Hanly JG, Kozora E, Beyea SD, Birnnaum J: Nervous system disease in systemic lupus erythematosus: current status and future directions. Arthritis Rheumatol 71: 33-42, 2019

8)Menon S, Jameson-Shortall E, Newman SP, Hall-Craggs MR, Chinn R, et al: A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis Rheum 42: 735-741, 1999

9)Gerosa M, Poletti B, Pregnolato F, Castellino G, Lafronza A, et al: Antiglutamate receptor antibodies and cognitive impairment in primary antiphopholipid syndrome and systemic lupus erythematosus. Front Immunol 7: 5, 2016［doi: 10.3389/fimmu.2016.00005］

10)Sanna G, Bertolaccini ML, Cuadrado MJ, Laing H, Khamashta MA, et al: Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol 30: 985-992, 2003

11)Chapman J, Rand JH, Brey RL, Levine SR, Blatt I, et al: Non-stroke neurological syndromes associated with antiphospholipid antibodies: evaluation of clinical and experimental studies. Lupus 12: 514-517, 2003

12)DeGiorgio LA, Konstantinov KN, Lee SC, Hardin JA, Volpe BT, et al: A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med 7: 1189-1193, 2001

13)Kowal C, Degiorgio LA, Lee JY, Edgar MA, Huerta PT, et al: Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc Natl Acad Sci U S A 103: 19854-19859, 2006

14)Yoshio T, Okamoto H, Hirohata S, Minota S: IgG anti-NR2 glutamate receptor autoantibodies from patients with systemic lupus erythematosus activated endothelial cells. Arthritis Rhuem 65: 457-463, 2013

15)Bonfa E, Golombek SJ, Kaufman LD. Skelly S, Weissbach H, et al: Association between lupus psychosis and anti-ribosomal P protein antibodies. N Engl J Med 317: 265-271, 1987

16)Katzav A, Solodeev I, Brodsky O, Chapman J, Pick CG, et al: Induction of autoimmune depression in mice by anti-ribosomal P antibodies via the limbic system. Arthritis Rhuem 56: 938-948, 2007

17)Massardo L, Bravo-Zehnder M, Calderón J, Flores P, Padilla O, et al: Anti-N-methyl-D-asparate receptor and anti-ribosomal-P autoantibodies contribute to cognitive dysfunction in systemic lupus erythematosus. Lupus 24: 558-568, 2015

18)Hanly JG, Urowitz MB, Su L, Bae SC, Gordon C, et al: Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus. Ann Rheum Dis 70: 1726-1732, 2011

19)Colasanti T, Delunardo F, Marqutti P, Vacirca D, Piro E, et al: Autoantibodies involved in neuropsychiatric manifestations associated with systemic lupus erythematosus. J Neuroimmunol 212: 3-9, 2009

20)Hirohata S, Miyamoto T: Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement. Arthritis Rheum 33: 644-649, 1990

21)Fragoso-Loyo H, Richaud-Patin Y, Orozco-Narváez A, Dávila-Maldonado L, Atisha-Fregoso Y, et al: Interleukin-6 and chemokines in the neuropsychiatric manifestations of systemic lupus erythematosus. Arthritis Rheum 56: 1242-1250, 2007

22)Shiozawa S, Kuroki Y, Kim M, Hirohata S, Ogino T: Interferon-alpha in lupus psychosis. Arthritis Rheum 35: 417-422, 1992

23)Magro-Checa C, Schaarenburg RA, Beaart HJ, Huizinga TW, Steup-Beekman GM, et al: Complement levels and anti-C1q autoantibodies in patients with neuropsychiatric systemic lupus erythematosus. Lupus 25: 878-888, 2016

24)Cohen D, Rijnink EC, Nabuurs RJ, Steup-Beekman GM, Versluis MJ, et al: Brain histopathology in patients with systemic lupus erythematosus: identification of lesions associated with clinical neuropsychiatric lupus syndromes and the role of complement. Rheumatology (Oxford) 56: 77-86, 2017

25)Hanly JG, Urowitz MB, Sanchez-Guerrero J, Bae SC, Gordon C, et al: Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Atrhritis Rhuem 56: 265-273, 2007

26)Shimojima Y, Matsuda M, Gono T, Ishii W, Ikeda S: Relationship between clinical factors and neuropsychiatric manifestations in systemic lupus erythematosus. Clin Rheumatol 24: 469-475, 2005

27)Jarpa E, Babul M, Calderón J, González M, Martínez ME, et al: Common mental disorders and psychological distress in systemic lupus erythematosus are not associated with disease activity. Lupus 20: 58-66, 2011

28)Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, et al: Derivation and validation of Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64: 2677-2686, 2012

29)Karassa FB, Afeltra A, Ambrozic A, Chang DM, De Keyser F, et al: Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 54: 312-324, 2006

30)Bertsias GK, Boumpas DT: Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations. Net Rev Rheumatol 6: 358-367, 2010

31)Hirohata S, Kanai Y, Mitsuo A, Tokano Y, Hashimoto H, et al: Accuracy of cerebrospinal fluid IL-6 testing for diagnosis of lupus psychosis. A multicenter retrospective study. Clin Rheumatol 28: 1319-1323, 2009

32)Uzawa A, Mori M, Masuda H, Ohtani R, Uchida T, et al: Interleukin-6 analysis of 572 consecutive CSF samples from neurological disorders: A special focus on neuromyelitis optica. Clin Chim Acta 469: 144-149, 2017

33)Kasitanon N, Louthrenoo W, Piyasirisilp S, Sukitawu W, Wichainun R: Neuropsychiatric manifestations in Thai patients with systemic lupus erythematosus. Asian Pac J Allergy Immunol 20: 179-185, 2002

34)Appenzeller S, Cendes F, Costallat LT: Epileptic seizures in systemic lupus erythematosus. Neurology 63: 1808-1812, 2004

35)González-Duarte A, Cantú-Brito CG, Ruano-Calderón L, García-Ramos G: Clinical description of seizures in patients with systemic lupus erythematosus. Eur Neurol 59: 320-323, 2008

36)Bertsias GK, Loannidis JP, Aringer M, Bollen E, Bombardieri S, et al: EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 69: 2074-2082, 2010

37)月田和人, 三宅啓史, 景山　卓,末長敏彦: 頭部MRI造影FLAIR像が治療方針の決定や病態の考察に有用であったneuropsychiatric systemic lupus erythematosusの1例. 臨床神経58: 414-417, 2018

38)Kelley BP, Corrigan JJ, Patel SC, Griffith BD: Neuropsychiatric lupus with antibody-mediated striatal encephalitis. AJNR Am J Neuroradiol 39: 2263-2269, 2018

39)Raymond AA, Zariah AA, Samad SA, Chin CN, Kong NC: Brain calcification in patients with cerebral lupus. Lupus 5: 123-128, 1996

40)Luyendijk J, Steens SC, Ouwendijk WJ, Steup-Beekman GM, Bollen EL, et al: Neuropsychiatric systemic lupus erythematosus: lessons learned from magnetic resonance imaging. Arthritis Rheum 63: 722-732, 2011

41)Sarbu N, Alobeidi F, Toledano P, Espinosa G, Giles I, et al: Brain abnormalities in newly diagnosed neuropsychiatric lupus: Systematic MRI approach and correlation with clinical and laboratory data in a large multicenter cohort. Autoimmun Rev 14: 153-159, 2015

42)Katsumata Y, Harigai M, Kawaguchi Y, Fukasawa C, Soejima M, et al: Diagnostic reliability of magnetic resonance imaging for central nervous system syndrome in systemic lupus erythematosus: a prospective cohort study. BMC Musculoskelet Disord 11: 13, 2010［doi: 10.1186/1471-2474-11-13］

43)Birnbaum J, Petri M, Thompson R, Izbudak I, Kerr D: Distinct subtypes of myelitis in systemic lupus erythematosus. Arthritis Rheum 60: 3378-3387, 2009

44)Zhang X, Zhaohul Z, Zhang F, Shu H, Li F, et al: Diagnostic value of single-photon-emission computed tomography in severe central nervous system involvement of systemic lupus erythematosus: a case-control study. Arthritis Care Res (Hoboken) 53: 845-849, 2005

45)Kodama K, Okada S, Hino T, Takabayashi K, Nawata Y, et al: Single photon emission computed tomography in systemic lupus erythematosus with psychiatric symptoms. J Neurol Neurosurg Psychiatry 58: 307-311, 1995

46)Waterloo K, Omdal R, Sjöholm H, Koldingsnes W, Jacobsen EA, et al: Neuropsychological dysfunction in systemic lupus erythematosus is not associated with changes in cerebral blood flow. J Neurol 248: 595-602, 2001

47)Sibbitt WL Jr, Sibitt RR, Brooks WM: Neuroimaging in neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 42: 2026-2038, 1999

48)Hanada K, Hosono M, Kudo T, Hitomi Y, Yagyu Y, et al: Regional cerebral blood flow in the assessment of major depression and Alzheimer's disease in the early elderly. Nucl Med Commun 27: 535-541, 2006

49)Fong TG, Bogardus ST Jr, Daffary A, Auerbach E, Blumenfeld H, et al: Cerebral perfusion changes in older delirious patients using 99mTc HMPAO SPECT. J Gerontol A Biol Sci Med Sci 61: 1294-1299, 2006

50)Barile-Fabris L, Ariza-Andraca R, Olguín-Ortega L, Jara LJ, Fraga-Mouret A, et al: Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis 64: 620-625, 2005

51)Mitsikostas DD, Sfikakis PP, Goadsby PJ: A meta-analysis for headache in systemic lupus erythematosus: the evidence and the myth. Brain 127: 1200-1209, 2004

52)Mikdashi J, Krumholz A, Handwerger B: Factors at diagnosis predict subsequent occurrence of seizures in systemic lupus erythematosus. Neurology 64: 2102-2107, 2005

53)Rosove MH, Brewer PM: Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 117: 303-308, 1992

54)Muñoz-Rodriguez FJ, Font J, Cervera R, Reverter JC, Tàssies D, et al: Clinical study and follow-up of 100 patients with the antiphospholipid syndrome. Semin Arthritis Rheum 29: 182-190, 1999

55)Okuma H, Kitagawa Y, Yasuda T, Tokuoka K, Takagi S: Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome. Int J Med Sci 7: 15-18, 2009

56)日本脳卒中学会　脳卒中ガイドライン委員会: 脳卒中治療ガイドライン2015. 協和企画, 東京, 2015

57)Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, et al: The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 332: 993-997, 1995

58)Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh H, et al: A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 349: 1133-1138, 2003

59)Finazzi G, Marchioli R, Brancaccio V, Schinco P, Wisloff F, et al: A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome. J Thromb Haemost 3: 848-853, 2005

60)Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, Brey R, Crowther M, et al: Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus 20: 206-218, 2011

61)Harrison MJ, Morris KA, Horton R, Toglia J, Barsky J, et al: Results of intervention for lupus patients with self-perceived cognitive difficulties. Neurology 65: 1325-1327, 2005

62)McLaurin EY, Holliday SL, Williams P, Brey RL: Predictors of cognitive dysfunction in patients with systemic lupus erythematosus. Neurology 64: 297-303, 2005

63)Petri M, Naqibuddin M, Sampedro M, Omdal R, Carson KA: Memantine in systemic lupus erythematosus: a randomized, double-blind placebo-controlled trial. Semin Arhthritis Rheum 41: 194-202, 2011

64)Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, et al: Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1000 patients. Medicine (Baltimore) 72: 113-124, 1993

65)Joseph FG, Lammie GA, Scolding NJ: CNS lupus: A study of 41 patients. Neurology 69: 644-654, 2007

66)Cervera R, Asherson RA, Font J, Tikly M, Pallarés L, et al: Chorea in the antiphospholipid syndrome: clinical, radiologic, and immunologic characteristics of 50 patients from our clinics and the recent literature. Medicine (Baltimore) 76: 203-212, 1997

67)Lu X, Gu Y, Wang Y, Chen S, Ye S: Prognostic factors of lupus myelopathy. Lupus 17: 323-328, 2008

68)Kovacs B, Lafferty T, Brent L, DeHoratius R: Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature. Ann Rheum Dis 59: 120-124, 2000

69)Saison J, Costedoat-Chalumeau N, Maucort-Boulch D, Iwaz J, Marignier R, et al: Systemic lupus erythematosus-associated acute transverse myelitis: manifestations, treatments, outcomes, and prognostic factors in 20 patients. Lupus 24: 74-81, 2015

70)D'Cruz DP, Mellor-Pita S, Joven B, Sanna G, Allanson J, et al: Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus-like disease: good functional outcome and relevance of antiphospholipid antibodies. J Rheumatol 31: 280-285, 2004

71)Katsiari CG, Giavri I, Mitsikostas DD, Yiannopoulou KG, Sfikakis PP. Acute transverse myelitis and antiphospholipid antibodies in lupus. No evidence for anticoagulation. Eur J Neurol 18: 556-563, 2011

72)Toledano P, Orueta R, Rodríguez-Pintó I, Valls-Solé J, Cervera R, et al: Peripheral nervous system involvement in systemic lupus erythematosus: Prevalence, clinical and immunological characteristics, treatment and outcome of a large cohort from a single centre. Autoimmun Rev 16: 750-755, 2017

73)Florica B, Aghdassi E, Su J, Gladman DD, Urowitz MB, et al: Peripheral neuropathy in patients with systemic lupus erythematosus. Semin Arthritis Rheum 41: 203-211, 2011

74)Xianbin W, Mingyu W, Dong X, Huiying L, Yan X, et al: Peripheral neuropathies due to systemic lupus erythematosus in China. Medicine (Baltimore) 94: e625, 2015［doi: 10.1097/MD.0000000000000625］